Pharmacoproteomics of obesity: definitions, role and a case study of dynamics of human plasma proteome

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.10, 2011-10, pp. : 1363-1365

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Role of pharmacoproteomics in the development of personalized medicine

By Jain KK

Pharmacogenomics, Vol. 5, Iss. 3, 2004-04 ,pp. : 331-336

Future Medicine

Access to resources Recommend Favorite

Interview with Dr. Young-Ki Paik, President of the Human Proteome Organization (HUPO): Pharmacoproteomics and the Approaching Wave of “Proteomics Diagnostics”

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. : 243-248

Bentham Science Publishers

Access to resources Recommend Favorite

Medicinal Chemistry Meets Proteomics: Fractionation of the Human Plasma Proteome

Current Medicinal Chemistry, Vol. 20, Iss. 4, 2013-02 ,pp. : 483-490

Bentham Science Publishers

Access to resources Recommend Favorite

Role of the constitutive androstane receptor in obesity and type 2 diabetes: a case study of the endobiotic function of a xenobiotic receptor

By Jiang Mengxi Xie Wen

Drug Metabolism Reviews, Vol. 45, Iss. 1, 2013-02 ,pp. : 156-163

Informa Healthcare

Access to resources Recommend Favorite

The Role of Obesity in Cardiomyopathy and Nephropathy

Current Pharmaceutical Design, Vol. 20, Iss. 9, 2014-03 ,pp. : 1409-1417

Bentham Science Publishers

Access to resources Recommend Favorite